{"classes":[{"categories":[{"measurements":[{"comment":"Not reached","groupId":"OG000","lowerLimit":"39.9","upperLimit":"NA","value":"49.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"}],"units":"Participants"}],"description":"Time to progression (TTP) is defined as the time from protocol therapy initiation until documented progression, censored at date last known progression-free for those who have not progressed.","dispersionType":"95% Confidence Interval","groups":[{"description":"* Cycles 1-9\n\n  * Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle\n  * Lenalidomide is administered orally on days 1-21 on a 28 days cycle\n  * Dexamethasone is administered orally on days 1, 8, 15, 22 on a 28 days cycle\n* Cycle 10-24\n\n  * Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle\n  * Lenalidomide is administered orally on days 1-21 on a 28 days cycle\n* Supportive measures consistent with optimal patient care may be given throughout the study\n\nIxazomib: Oral, proteasome inhibitor\n\nLenalidomide: Oral, immunomodulatory agent\n\nDexamethasone: Oral, steroid","id":"OG000","title":"Ixazomib"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"The time from protocol therapy initiation until documented progression, censored at date last known progression-free for those who have not progressed or up to 60 months post initiation of therapy","title":"Time To Progression","type":"SECONDARY","unitOfMeasure":"months"}